On January 8, 2026, Jingtai investment company Jingfeng Medical was listed on the Hong Kong Stock Exchange (stock code: 02675. HK), becoming the third listed surgical robot company in China after Tianzhihang and Minimally Invasive Robots, and is also a key member of the "Four Tigers of Domestic Surgical Robots".

Jingfeng Medical: Full-stack self-research to create a benchmark for domestic surgical robots

Since its establishment in 2017, Jingfeng Medical has always focused on the frontiers of minimally invasive and non-invasive surgery, and has built a complete product matrix covering three major technical paths: multi-port laparoscope, single-port laparoscopy and natural lumen path.

The company is the first company in China and the second in the world to obtain three types of surgical robot registration certificates at the same time, and its core products, Jingfeng ® multi-hole laparoscopic surgical robot (MP series) and single-port laparoscopic surgical robot (SP series), have been commercialized and obtained EU CE certification. As of June 2025, its core products have completed more than 14,000 clinical surgeries, and the domestic sales of multi-hole robots will rank first among domestic brands in 2024.

Relying on a high-level R&D team of 267 people and 748 global patents, Jingfeng Medical continues to make breakthroughs in seven core technology modules such as intelligent control, precision machinery, and AI algorithms, forming a full-chain competitive barrier from R&D, production to commercialization.

In the 100-billion-level high-growth track, Jingfeng Medical is accelerating the breaking of the foreign monopoly pattern with solid technology accumulation and rapid clinical penetration.